COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Funding Opportunities & Translational Resources

The National Cancer Institute’s Nanodelivery Systems and Devices Branch has compiled the following list of funding opportunities and translational resources that may be of interest to nanotech developers. Click the link for each announcement to learn more.

Alliance IRCN:

  • PAR 17-240 – Innovative Research in Cancer Nanotechnology (R01).  The proposal should address major barriers in cancer biology and/or oncology using nanotechnology and should emphasize a fundamental understanding of nanomaterial and/or nanodevice interactions with biological systems. Remaining receipt dates: Nov 21, 2019, and May 21, 2020.  We anticipate this PAR will be renewed.


Clinical/Translational Programs and Funding Opportunities:

  • PAR-18-560: Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required).  The FOA supports research projects that implement early phase (Phase 0, I, and II) investigator-initiated clinical trials focused on cancer-targeted diagnostic and therapeutic interventions of direct relevance to the research mission of NCI’s Division of Cancer Treatment and Diagnosis (DCTD).  Due Standard Dates through Jan 8, 2021.
  • PAR-18-011: Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01 Clinical Trial Required).  This FOA supports clinical trials in the preliminary evaluation of the safety and efficacy of imaging agents, and the assessment of imaging systems, image processing, and other quantitative tools.  Due October 11, 2019, and February 14, 2020.
  • NCI Experimental Therapeutics Program (NExT): Please note that the NExT Program is not a grant mechanism; applications with exceptional science cannot be accepted without a clear path to the clinic or potential benefit to patients. The mission of the NExT Program is to advance clinical practice and bring improved therapies to patients with cancer by supporting the most promising new drug discovery and development projects. Awardees will not necessarily receive direct funding; rather, the NCI may allocate various contract and grant resources toward the implementation and development of submitted projects. The NCI will partner with successful applicants to facilitate the milestone-driven progression of new anticancer drugs (small molecules, biologics) and imaging agents towards clinical evaluation and registration.  See application instructions.
  • The Experimental Therapeutics Clinical Trials Network (ETCTN).  The ETCTN supports the early phase clinical trials of NCI Investigational New Drug (IND) agents by providing investigators and programs with expertise in early drug development and translational research.  There are two expired FOAs for this program, but Investigators are encouraged to check back to the Network website link above.
  • RFA-CA-19-007 (UM1) is open to any qualified applicant and solicits applications from multidisciplinary groups that can assemble an appropriate infrastructure and conduct phase 0, 1, 2, pilot and other experimental therapeutics clinical trials involving agents for which NCI have received the IND status.
  • RFA-CA-19-008 (U24) intends to create Pharmacokinetics Resource Laboratories to support the ETCTN.


Basic/Applied Science Programs and Funding Opportunities:


Team Science Funding Opportunities